Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00259831Phase 3Completed

Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults

Role: lead

NCT00527969Phase 2Completed

Cognitive, Emotional, Physical and Psychosocial Effects of Panax Quinquefolius L

Role: lead

NCT00435968Phase 2Completed

Safety and Immune Enhancing Effects of Acute Dosing of COLD-fX in Healthy Adults

Role: lead

NCT00255307Phase 2Completed

Pilot Evaluation of CVT-E002 in Pediatric Upper Respiratory Tract Infection.

Role: lead

All 4 trials loaded